CompletedNot Applicable

Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

Austria, Colombia155 participantsStarted 2017-06-20

Plain-language summary

This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of NIIPPU participants treated with Humira® in the real-life setting.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
✓. \>= 2+ anterior chamber cells \[Standardization of Uveitis Nomenclature (SUN) criteria\]
✓. \>= 2+ vitreous haze \[National Eye Institute (NEI)/SUN criteria\]

What they're measuring

Proportion of participants who achieve treatment response at any of the follow-up visits

Timeframe: Up to Month 12

Trial details

NCT IDNCT03155243

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-02-24

View on ClinicalTrials.gov More Uveitis trials